Khosla Ventures Acquisition Co. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2021 and is based in Menlo Park, California.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
OpenAI investor and Sun Microsystems co-founder Vinod Khosla said that even at 68, he works 80 hours a week and intends to do so for the next 25 years. What Happened: Khosla said he would even try and extend his life using Peter Thiel's anti-aging methods if they work, just so he can continue to work and invest in companies. Khosla was on The Cerebral Valley podcast where he underlined that he will continue his grind for as long as his health permits. He founded his investment firm Khosla Ventures Acquisition Co. (NASDAQ:KVSA) and says he will continue to invest for the next 25 years. "I’ve seen too many people retire and grow old. So, I clearly plan to do — health permitting — this
Along with the hundreds of announced SPAC mergers and closed deals in 2021 came a handful of SPAC deals that were terminated. Here’s a look at what it means for the SPACs that called off mergers. What Happened: SPACs can terminate deals for numerous reasons including a change in valuation sentiment, missing deadlines or news items coming from the acquisition target. When SPACs call off deals, they lose the time and money spent to research and attempt to close a deal. The termination also sends the team back to the drawing board to try and find a new acquisition target. SPACs have a deadline date to meet, which is typically 24 months from its IPO date. With deals called off, many companies
BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that it will voluntarily transfer the listing of its Class A common stock, par value $0.0001 per share ("Class A Common Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York Stock Exchange ("NYSE") in connection with, and following the closing of, the previously announced business combination (the "Business Combination") with Valo Health, Inc. ("Valo"), the wholly owned subsidiary of Valo Health, LLC ("Valo Health"). The shares of Class A Co
SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)
SC 13G - Khosla Ventures Acquisition Co. (0001841873) (Subject)
15-12G - Khosla Ventures Acquisition Co. (0001841873) (Filer)
8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)
25-NSE - Khosla Ventures Acquisition Co. (0001841873) (Subject)
10-Q - Khosla Ventures Acquisition Co. (0001841873) (Filer)
8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)
10-Q - Khosla Ventures Acquisition Co. (0001841873) (Filer)
8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)
DEFA14A - Khosla Ventures Acquisition Co. (0001841873) (Filer)
DEF 14A - Khosla Ventures Acquisition Co. (0001841873) (Filer)
8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)
MENLO PARK, Calif., Dec. 4, 2023 /PRNewswire/ -- Khosla Ventures Acquisition Co. (the "Company") (NASDAQ:KVSA) today announced that it will redeem all of its outstanding shares of Class A common stock that were issued in its initial public offering and not previously redeemed (the "public shares"), effective as of the close of business on December 11, 2023, as the Company will not consummate an initial business combination on or prior to December 8, 2023. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combination by December 8, 2023, then the Company will: (i) cease all operations except for the purpose of winding up,
BOSTON and MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by affiliates of Khosla Ventures, LLC, announced today that both companies have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately. Both parties decided to terminate the Business Combination based on current market conditions, particularly in the biot
BOSTON and MENLO PARK, Calif., Nov. 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the private placement of common stock ("PIPE") investment in connection with their previously announced business combination had expanded from $168.5M to over $200M exceeding initial targets.
BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that it will voluntarily transfer the listing of its Class A common stock, par value $0.0001 per share ("Class A Common Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York Stock Exchange ("NYSE") in connection with, and following the closing of, the previously announced business combination (the "Business Combination") with Valo Health, Inc. ("Valo"), the wholly owned subsidiary of Valo Health, LLC ("Valo Health"). The shares of Class A Co
BOSTON and MENLO PARK, Calif., Oct. 25, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the Special Meeting of Stockholders ("Special Meeting") to vote on the approval and adoption of KVSA's business combination agreement with Valo Health, LLC ("Valo Health") and the wholly owned subsidiary of Valo Health, Valo Health, Inc. ("Valo"), will be held via live telecast on November 16, 2021 at 10:00 a.m. ET. Following the business combination, Valo will be a wholly owned subsidiary of KVSA. Valo Health is a technology company built to tran
BOSTON, June 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. ("KVAC") (NASDAQ: KVSA), a special purpose acquisition company founded by affiliates of Khosla Ventures, LLC, announced today that they have entered into a definitive merger agreement. A Flagship Pioneering company, Valo is building a fully-integrated, end-to-end approach to developing drugs from target discovery through approval using its Opal Computational Platform™. Built on large scale, high quality longitudinal and omics data, Valo'